RxDoctor Payments Data

Tracy George, MD

Anatomic Pathology & Clinical Pathology · Salt Lake City, UTNPI 1083761142

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $93,081 of the $134,316 with a category attached, or 69.3%. 8 manufacturers reported payments, led by Blueprint Medicines Corporation at 56.9% of the total. Reporting peaked in 2024 at $35,298 and has fallen 68.5% since, to $11,117 in 2025. Among anatomic pathology & clinical pathology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$134,316in general payments, 2019–2025

Across 84 payments — averaging $1599.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Blueprint Medicines Corporation$76K
  • Incyte Corporation$44K
  • Stemline Therapeutics Inc.$9K
  • Bristol Myers Squibb$3K
  • Beckman Coulter, Inc.$2K
  • Sanofi$210
  • plus $241 from 2 others
$9,904in research payments, 2019–2025

Across 8 payments — averaging $1238.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$4K
  • Incyte Corporation$4K
  • Novartis$1K

What the payments were for

  • Consulting fees$93,08169%
  • Speaking & faculty fees$36,35727%
  • Travel & lodging$2,4062%
  • Food & beverage$2,3812%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,316 in reported general payments places this provider in the 95th percentile of 57 anatomic pathology & clinical pathology providers in Utah.

See all anatomic pathology & clinical pathology providers in Utah

Medicare billing

Part B allowed, 2024
$2,687
Medicare patients
66
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →